Literature DB >> 9467666

Tolerance and cancer: a critical issue in tumor immunology.

E M Sotomayor1, I Borrello, H I Levitsky.   

Abstract

Self-antigens are the most relevant and abundant antigens to which the host's immune system must be tolerant. Induction and maintenance of tolerance to self-antigens is mediated by several mechanisms that prevent inappropriate damage to normal tissues. However, these same mechanisms may impose potential barriers for the full development of effective immune responses against antigens expressed by tumors. A critical issue in tumor immunology is whether antigen presented by a progressively expanding tumor cell population results in T-cell tolerance. Utilizing a T cell receptor transgenic mice specific for a model tumor antigen expressed on a B-cell lymphoma, recently we have obtained direct evidence supporting the existence of tumor-induced antigen-specific tolerance. A better identification and understanding of the factor(s) involved in tumor-induced tolerance has clear implications for the development of novel cancer immunotherapies aimed at safely breaking tolerance, for example, releasing the brakes on antitumor immune responses while still limiting the induction of undesirable autoimmune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9467666     DOI: 10.1615/critrevoncog.v7.i5-6.30

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  14 in total

Review 1.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

Review 2.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.

Authors:  Taku Okazaki; Shunsuke Chikuma; Yoshiko Iwai; Sidonia Fagarasan; Tasuku Honjo
Journal:  Nat Immunol       Date:  2013-12       Impact factor: 25.606

3.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Authors:  Gang Zhou; Charles G Drake; Hyam I Levitsky
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

4.  Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles.

Authors:  T Doan; K Herd; M Street; G Bryson; G Fernando; P Lambert; R Tindle
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.

Authors:  Ken-Yu Lin; Dan Lu; Chien-Fu Hung; Shiwen Peng; Lanqing Huang; Chunfa Jie; Francisco Murillo; Jesse Rowley; Ya-Chea Tsai; Liangmei He; Dae-Jin Kim; Elizabeth Jaffee; Drew Pardoll; T-C Wu
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

Review 6.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 7.  Immunotherapy for myeloid leukemias: current status and future directions.

Authors:  K el-Shami; B D Smith
Journal:  Leukemia       Date:  2008-06-19       Impact factor: 11.528

8.  Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.

Authors:  Kyle K Payne; Christine K Zoon; Wen Wan; Khin Marlar; Rebecca C Keim; Mehrab Nasiri Kenari; A Latif Kazim; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2013-10-25       Impact factor: 4.872

9.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Authors:  Paolo Serafini; Stephanie Mgebroff; Kimberly Noonan; Ivan Borrello
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.

Authors:  Yanjun Liu; Yibing Peng; Michael Mi; Jose Guevara-Patino; David H Munn; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.